MODERN BIOMARKERS - PREDICTORS OF EARLY CARDIOVASCULAR AGEING (literature review)

  M.Abdykassymova1

1 Senior lecturer Al-Farabi Kazakh National University, Almaty, Kazakhstan.

merei1808@mail.ru <https://orcid.org/0000-0002-5365-5508>

K. Abzaliyev1

1 Doctor of medical science, professor Al-Farabi Kazakh National University, Almaty, Kazakhstan.

abzaliev\_kuat@mail.ru,<https://orcid.org/0000-0003-2452-854X>

Ghazwan Butrous2

2 Doctor of medical science, professor University of Kent, Canterbury, UK.

g.butrous@kent.ac.uk, <https://orcid.org/0000-0002-6640-6332>

S. Abzaliyeva3

3 Doctor of medical science, professor Asfendiyarov Kazakh National Medical University,Almaty,Kazakhstan.

abzaliyeva.symbat@gmail.com, <https://orcid.org/0009-0004-9802-0129>

A. Kurmanova1

1 Doctor of medical science, professor Al-Farabi Kazakh National University, Almaty, Kazakhstan.

alm\_kurmanova@mail.ru, <https://orcid.org/0000-0002-1859-3903>

R. Bitemirova1

1 Senior lecturer Al-Farabi Kazakh National University, Almaty, Kazakhstan.

 r.bitemir@gmail.com <https://orcid.org/0000-0002-5228-6018>

 D.Sundetova1

1 Senior lecturer Al-Farabi Kazakh National University, Almaty, Kazakhstan.

sdiana92@mail.ru , <https://orcid.org/0000-0003-2343-869X>

U. Sagalbayeva1

1 Senior lecturer Al-Farabi Kazakh National University, Almaty, Kazakhstan.

Ulya\_sagalbayeva@mail.ru; <https://orcid.org/0000-0001-7903-9116>

A. Bugibayeva1

1 Senior lecturer Al-Farabi Kazakh National University, Almaty, Kazakhstan.

bota\_88.20@mail.ru; <https://orcid.org/0000-0003-1417-2711>

 N. Baizhigitova4

4 Medical Director Smart Health University City, Almaty, Kazakhstan.

abzaliev\_kuat@mail.ru; <https://orcid.org/0000-0003-2452-854X>

A. Kenzhebaeva1

1 doctor-intern Al-Farabi Kazakh National University, с

adikosyak@gmail.com; ORCID <https://orcid.org/0009-0004-2678-1922>

 М.Baurzhan4

4Head of the Department of Science, Acting Associate Professor Academy of Physical Culture and Mass Sports, Almaty, Kazakhstan.

Madina\_baurzhan@mail.ru; https://orcid.org/0000-0003-1244-8673

**СОВРЕМЕННЫЕ БИОМАРКЕРЫ – ПРЕДИКТОРЫ РАННЕГО СЕРДЕЧНО-СОСУДИСТОГО СТАРЕНИЯ (обзор литературы)**

М.Абдыкасымова1

1 старший преподаватель, Казахский Национальный Университет имени Аль-Фараби, Алматы, Казахстан. merei1808@mail.ru <https://orcid.org/0000-0002-5365-5508>

K. Абзалиев 1

1 д.м.н профессор, Казахский Национальный Университет имени Аль-Фараби, Алматы,Казахстан.abzaliev\_kuat@mail.ru, <https://orcid.org/0000-0003-2452-854X>

Газван Бутрос (Ghazwan Butrous)2

2 д.м.н профессор,университет Кент, Англия,Великобритания.

g.butrous@kent.ac.uk, <https://orcid.org/0000-0002-6640-6332>

С.Абзалиева 3

3 д.м.н профессор КазНМУ им. С.Д. Асфендиярова, Алматы, Казахстан.

abzaliyeva.symbat@gmail.com, <https://orcid.org/0009-0004-9802-0129>

А.Курманова1

1 д.м.н профессор, Казахский Национальный Университет имени Аль-Фараби, Алматы, Казахстан. alm\_kurmanova@mail.ru, <https://orcid.org/0000-0002-1859-3903>

Р.Битемирова 1

1 старший преподаватель, Казахский Национальный Университет имени Аль-Фараби, Алматы, Казахстан. r.bitemir@gmail.com <https://orcid.org/0000-0002-5228-6018>

Д.Сундетова1

1 старший преподаватель, Казахский Национальный Университет имени Аль-Фараби, Алматы, Казахстан. s.diana@mail.ru <https://orcid.org/0000-0003-2343-869X>

У. Сагалбаева1

1 старший преподаватель, Казахский Национальный Университет имени Аль-Фараби, Алматы, Казахстан. Ulya\_sagalbayeva@mail.ru https://orcid.org/0000-0001-7903-9116

A. Бугибаева1

1, старший преподаватель, Казахский Национальный Университет имени Аль-Фараби, Алматы, Казахстан. bota\_88.20@mail.ru <https://orcid.org/0000-0003-1417-2711>

 Н. Байжигитова4

4 медицинский директор, TOO «Smart Health University City», Алматы, Қазақстан.

abzaliev\_kuat@mail.ru; <https://orcid.org/0000-0003-2452-854X>

A. Кенжебаева1

1 врач интерн Казахский Национальный Университет имени Аль-Фараби, Алматы, Казахстан. adikosyak@gmail.com <https://orcid.org/0009-0004-2678-1922>

 М.Бауржан 4

4руководитель отдела науки, и.о. Ассоцированный профессор Академия физической культуры и массового спорта, Алматы, Казахстан.

Madina\_baurzhan@mail.ru ; https://orcid.org/0000-0003-1244-8673

**ЖҮРЕК-ҚАН ТАМЫРЛАРДЫҢ ЕРТЕ ҚАРТАЮЫН БОЛЖАУШЫ ЗАМАНАУИ БИОМАРКЕЛЕР (әдебиеттерге шолу)**

М.Абдыкасымова1

1 аға оқытушы Әл-Фараби атындағы Қазақ Ұлттық Университеті, Алматы, Қазақстан merei1808@mail.ru <https://orcid.org/0000-0002-5365-5508>

K. Абзалиев 1

1 м.ғ,д профессор, Әл-Фараби атындағы Қазақ Ұлттық Университеті, Алматы, Қазақстан.abzaliev\_kuat@mail.ru, <https://orcid.org/0000-0003-2452-854X>

Газван Бутрос (Ghazwan Butrous)2

2 д м.ғ,д профессор, Кент университеті, Англия, Ұлыбритания.

g.butrous@kent.ac.uk, <https://orcid.org/0000-0002-6640-6332>

С.Абзалиева 3

3 м.ғ,д профессор С.Д.Асфендияров атындағы ҚазҰМУ, Алматы, Қазақстан.

abzaliyeva.symbat@gmail.com, <https://orcid.org/0009-0004-9802-0129>

А.Курманова1

1 м.ғ,д профессор, Әл-Фараби атындағы Қазақ Ұлттық Университеті, Алматы, Қазақстан.alm\_kurmanova@mail.ru, <https://orcid.org/0000-0002-1859-3903>

Р.Битемирова 1

1 аға оқытушы Әл-Фараби атындағы Қазақ Ұлттық Университеті, Алматы, Қазақстан. r.bitemir@gmail.com, <https://orcid.org/0000-0002-5228-6018>

Д.Сундетова1

1 аға оқытушы, Әл-Фараби атындағы Қазақ Ұлттық Университеті, Алматы, Қазақстан. sdiana92@mail.ru <https://orcid.org/0000-0003-2343-869X>

У. Сагалбаева1

1 аға оқытушы, Әл-Фараби атындағы Қазақ Ұлттық Университеті, Алматы, Қазақстан. Ulya\_sagalbayeva@mail.ru <https://orcid.org/0000-0001-7903-9116>

A. Бугибаева1

1 аға оқытушы, Әл-Фараби атындағы Қазақ Ұлттық Университеті, Алматы, Қазақстан. bota\_88.20@mail.ru <https://orcid.org/0000-0003-1417-2711>

 Н. Байжигитова4

4 медициналық директор, TOO «Smart Health University City», Алматы, Қазақстан.

abzaliev\_kuat@mail.ru; <https://orcid.org/0000-0003-2452-854X>

 A. Кенжебаева1

1 интерн дәрігер Әл-Фараби атындағы Қазақ Ұлттық Университеті, Алматы, Қазақстан. adikosyak@gmail.com <https://orcid.org/0009-0004-2678-1922>

М.Бауыржан 4

4ғылым бөлімінің басшысы, қауымдастырылған профессор М. А. Дене шынықтыру және бұқаралық спорт академиясы, Алматы, Қазақстан.

Madina\_baurzhan@mail.ru; https://orcid.org/0000-0003-1244-8673

**Автор-корреспондент:** Abzaliyeva Symbat Abulkhairovna, **д.м.н профессор**, Asfendiyarov Kazakh National Medical University,Almaty,Kazakhstan.

**Почтовый индекс:**

Адрес: г.Алматы, Баганашыл,Тан 56

Телефон:8-777-232-29-78

Электронная почта: abzaliyeva.symbat@gmail.com

 **MODERN BIOMARKERS - PREDICTORS OF EARLY CARDIOVASCULAR AGEING (literature review)**

**Annotation.** An analysis of the current state of the problem of studying biomarkers of human cardiovascular ageing was carried out based on an analysis of international experience. Ageing is an inevitable, constantly progressive systemic process, which is a significant risk factor for the development of most common chronic human diseases, including cardiovascular diseases. Therefore, studying markers of early cardiovascular ageing is a logical goal for developing measures to prevent the development of cardiovascular disease and improve the quality of life and prolong active longevity.

**Key words:** biomarkers of ageing, predictors of cardiovascular ageing, theories of ageing, regulation of ageing, longevity

**СОВРЕМЕННЫЕ БИОМАРКЕРЫ – ПРЕДИКТОРЫ РАННЕГО СЕРДЕЧНО-СОСУДИСТОГО СТАРЕНИЯ (обзор литературы)**

**Резюме**. На основе международного опыта, был проведён анализ современного состояния и проблем изучения биомаркеров

 сердечно-сосудистого старения человека.

Старение — неизбежный, постоянно прогрессирующий системный процесс, являющийся значимым фактором риска развития большинства распространённых хронических заболеваний человека, в том числе сердечно-сосудистых заболеваний. Изучение маркеров раннего сердечно-сосудистого старения является одним из значимых целей для разработки мер профилактики развития сердечно-сосудистых заболеваний, улучшения качества жизни и продления активного долголетия.

**Ключевые слова:** биомаркеры старения, предикторы сердечно-сосудистого старения, теории старения, регуляция старения, долголетие

**ЖҮРЕК-ҚАН ТАМЫРЛАРДЫҢ ЕРТЕ ҚАРТАЮЫН БОЛЖАУШЫ ЗАМАНАУИ БИОМАРКЕРЛЕР (әдебиеттерге шолу)**

**Түйіндеме** Халықаралық тәжірибеге сүйене отырып, адамның жүрек-қан тамырлары қартаюының биомаркерлерін зерттеудің қазіргі жағдайы мен мәселелеріне талдау жасалды.

 Қартаю-бұл адамның созылмалы ауруларының, соның ішінде жүрек-қан тамырлары ауруларының дамуында маңызды қауіп фактор болып табылатын, еріксіз, үнемі үдемелі жүретін жүйелі процесс. Жүрек-қан тамырларының ерте қартаюының маркерлерін зерттеу - жүрек-қан тамырлары ауруларының дамуының алдын алу, өмір сүру сапасын жақсарту және белсенді ұзақ өмір сүруді ұзарту бойынша шараларды әзірлеудің маңызды мақсаттарының бірі болып табылады.

**Түйін сөздер:** қартаю биомаркерлері, жүрек-қан тамырлары қартаюының болжаушылары, қартаю теориялары, қартаюды реттеу, ұзақ өмір сүру.

**Introduction**

According to World Health Organization (WHO) data from October 1, 2022, the number of people aged 60 years and older surpassed the number of children under 5 years of age in 2020 [1]. This trend underscores the urgent need to identify and determine the most significant biomarkers of ageing, which will hold immense value in assessing the health status of older and senescent individuals.

Over the past few centuries, the global population has experienced a progressive shift towards ageing. In 2017, the number of individuals aged 60 years and older worldwide reached 962 million, more than doubling from 1980 figures. By 2050, the elderly population is projected to double again, reaching approximately 2 billion [2].

Old age is recognized as the most significant risk factor for chronic age-related diseases. According to Zhendong D. Zhang et al. [ REF], over 90% of individuals over 65 years of age have at least one chronic disease, such as cardiovascular disease, cancer, dementia, diabetes, osteoarthritis, or osteoporosis, and more than 70% have at least two of these conditions. These data highlight the substantial socioeconomic burden that will be placed on healthcare systems. Therefore, studying the ageing process, maintaining health in older individuals, and developing methods for preventing and treating age-related diseases is crucial for extending the period of healthy ageing.

Ageing is a systemic process that affects various levels of biological organization. It is characterized by gradually inhibiting fundamental bodily functions, including regenerative and reproductive capabilities, leading to decreased adaptability to environmental conditions [3]. This decline in adaptability makes individuals less resilient to stress, diseases, and injuries, which ultimately makes death inevitable. Ageing is an inherently emerging, naturally developing, and destructive process that limits the body's adaptive capabilities, increases the likelihood of death, reduces life expectancy, and contributes to the development of age-related pathologies.

Currently, there are over 130 theories of ageing, among which the most studied are autointoxication, telomeric, free radical, genetic, and epigenetic theories [REF]. Particular attention is focused on ageing and longevity's genetic and epigenetic mechanisms [REF].

In recent years, there has been a growing surge in scientific meetings, articles, and books dedicated to anti-ageing methods, reflecting the widespread interest in this topic among the general public. Consequently, the search for biomarkers of ageing continues unabated, as such biomarkers would offer several advantages:

1. **Predicting Ageing Rate:** Biomarkers would provide a precise indication of an individual's position within their lifespan, allowing for accurate predictions regarding their ageing trajectory.
2. **Monitoring Ageing Processes:** Biomarkers would enable monitoring of the underlying mechanisms driving the ageing process rather than simply assessing the effects of age-related diseases.

# Ageing and risk of cardiovascular diseases

Ageing is a significant risk factor for most chronic diseases and functional impairments, and age-related diseases are the leading cause of death. Approximately 60% of all deaths are attributed to cardiovascular diseases, followed by oncological diseases, which account for 14% of all deaths [3].

Over the last four decades, medicine has shifted from treating diseases as "patient care" to further identifying and preventing risk factors before they lead to diseases as "health care". For instance, high cholesterol and high blood pressure are not diseases themselves but increase the risk of heart attacks and strokes. Similarly, ageing is not a disease but a significant risk factor for various diseases, including heart attacks, strokes, certain cancers, macular degeneration, osteoarthritis, neurodegeneration, and many more. The risk of cardiovascular disease doubles every 10 years after age 40, even after adjusting for other risk factors - similar to adding a new significant risk factor (smoking, hypertension, etc.) every decade [5]. Decades of cardiovascular research have shown that treating risk factors, even in patients without symptoms, prevents harm. Identifying biomarkers of ageing and associated health consequences will allow early detection of individuals at high age-related risk throughout their lifespan and in different clinical settings [6].

Even within the same age group, individuals exhibit varying disease risks and functional decline, highlighting the need for reliable biomarkers to track ageing processes and stages. The diversity of biological factors, lifestyles, and treatments further challenges biomarker identification. Therefore, no single biomarker can definitively assess healthy ageing [7].

Cardiovascular diseases are the leading cause of death and disability worldwide (as per the WHO), including Kazakhstan. The ability to reach the current maximum lifespan (≥110 years) in low-mortality countries is attributed to protection from cardiovascular disease, as this system is particularly susceptible to oxidative stress and inflammation and plays a crucial role in maintaining oxygen and metabolite delivery to vital organs [8]. These findings emphasize the need for specific cardiac markers that predict premature ageing and prevent adverse outcomes during ageing.

Centenarians (≥90 years) extend the human lifespan by evading or surviving major illnesses. Identifying specific biomarkers associated with exceptional longevity may provide insights into combating ageing-related diseases.

A 2020 study published in "Nature Communications" by Japanese researchers Hirata, Arai, Yuasa, Abe, Takayama, Sasaki, and Kunikomi examined the association of cardiovascular biomarkers and plasma albumin with exceptional survival to the highest ages [8]. They selected nine circulating biomarkers representing distinct cardioprotective and pathogenic pathways:

1.N-terminal pro-B-type natriuretic peptide (NT-proBNP)

 2.Erythropoietin

3.Adiponectin

4.Extracellular superoxide dismutase (EC-SOD or SOD3)

5.Interleukin-6

6.Tumor necrosis factor-alpha (TNF-alpha)

7.Angiopoietin-like protein 2 (Angptl2)

8.Cystatin C

9.Cholinesterase

 We comprehensively analyzed relevant scientific literature to understand better and assess healthy and pathological ageing indicators to identify risk markers for early involutional changes in the cardiovascular system and the development of age-associated cardiovascular diseases. We focused our literature search on peer-reviewed articles published in PubMed, Scopus, and Google Scholar, excluding non-peer-reviewed publications. We prioritized meta-analyses, systematic reviews, cohort studies, and cross-sectional studies, as these provide the most robust evidence. Our review summarizes current data on potential ageing biomarkers that are early predictors of cardiovascular ageing. These include:

1.Biochemical markers: NT-proBNP

2.Oxidative stress

3.Cystatin C

4.Сholinesterase

5.Inflammatory and Immunological markers

## B-type natriuretic peptide

Abiologically active analogue of NT-proBNP, causes natriuresis and diuresis, dilation of arteries and antagonism of the renin-angiotensin-aldosterone system, thereby counteracting hemodynamic disturbances in heart failure. The underlying mechanisms responsible for the association between low circulating NT-proBNP levels and exceptional survival are currently unclear, but a potential explanation can be considered. In the present review, centenarians and (semi-)centenarians showed a low prevalence of clinical and subclinical cardiovascular disease detected by ECG and low cardiometabolic risk profiles, except for a relatively high prevalence of chronic kidney disease. However, median NT-proBNP levels increased consistently with age regardless of cardiovascular status, reaching 1530 pg/mL in individuals aged ≥110 years. In addition, 42.9% of centenarians had NT-proBNP levels ≥1800 pg/ml, which is the threshold value for diagnosing heart failure in people over 75 years of age [13,14].

The study found that NT-proBNP, interleukin-6, cystatin C, and cholinesterase were significantly associated with increased survival to super centenary age, while adiponectin and erythropoietin were not significantly associated [8-11].

Furthermore, combined data from three prospective cohort studies: the Tokyo Centenarian Study (TCS), the Japanese Semicentenarian Study (JSS), and the Tokyo Oldest Study of General Health (TOOTH). The analytic cohort included a cohort of 1427 older adults of 36 centenarians (≥110 years), 572 semicentenarians (105–109 years), 288 centenarians (100–104 years) and 531 very old people (85–99 years) [12]. The concordance index (C-index) was calculated using Cox proportional hazards models to assess each biomarker's prognostic performance.

The finding suggested that adding each predictive biomarker (NT-proBNP, interleukin-6, cystatin C, and cholinesterase) to the baseline model significantly improved risk prediction with minimal optimism in the entire cohort. When stratified by age, the predictive power of the models decreased significantly, suggesting that age itself is the primary predictor.

 Thus, The base model weakly predicted mortality over age 105 (C-index 0.617 [95% CI; 0.577–0.656], optimism-adjusted C-index = 0.588). However, adding NT-proBNP, and to a lesser extent, cholinesterase, significantly improved prognosis at older ages (NT-proBNP: C-index, 0.653 [95% CI; 0.615–0.691], P = 0.001, C-index adjusted for optimism = 0.625; cholinesterase: C-index = 0.636 [95% CI; 0.596-0.676], P = 0.019, Optimism-adjusted C-index = 0.609, respectively).

## Oxidative Stress

Oxidative stress is when the body produces excess free radicals, which can damage cells [15]. This process involves the pathogenesis of various diseases, including Chronic heart failure (CHF) [16, 17]. Studies have shown that people with CHF have lower levels of an enzyme that helps protect cells from free radicals [REFERENCES NEEDED].

CHF is a significant health problem due to its high prevalence and mortality rates among working-age adults. Free radicals, produced in large quantities during oxidative stress in CHF patients, primarily damage the vascular endothelium and cardiomyocytes. They can also promote the activation of cytokines, which contributes to disease progression and often determines the prognosis in CHF patients [16, 17].

A 2018 study by Russian scientists Polunina et al. investigated 280 CHF patients and 60 healthy controls [18]. The patients were divided into groups depending on their left ventricular ejection fraction and the stage of their disease. The researchers found that the activity of superoxide dismutase (SOD), an antioxidant enzyme, was significantly lower in CHF patients compared to healthy individuals [18]. This suggests that oxidative stress plays a significant role in CHF pathogenesis.

## Cystatin C

Accurate and early detection of nephropathy is crucial for timely intervention with nephroprotective and cardioprotective therapies, thereby reducing the risk of cardiovascular diseases and mortality [19]. Cystatin C, a novel biomarker, holds promise as a more sensitive indicator of reduced glomerular filtration rate (GFR) compared to traditional methods like serum creatinine.

## Cholinesterase

As the prevalence of heart failure (HF) among older adults rises, it is increasingly important to consider not only the pathophysiology of HF but also the overall decline in health associated with ageing [20, 21]. Nutritional status plays a crucial role in the prognosis of HF mortality, necessitating proper assessment and intervention [10, 11]. In this regard, serum cholinesterase (ChE) levels have emerged as a potential new biomarker for nutritional status. ChE is a protein produced in the liver and is associated with prognosis in patients with HF.

Serum ChE levels as a potential biomarker for myocardial ischemia in stable coronary artery disease (CAD). A study involving 559 consecutive patients with suspected stable CAD and no prior cardiovascular history investigated the relationship between myocardial ischemia and serum cholinesterase (ChE) levels. The findings revealed that:

 1.Myocardial ischemia incidence significantly increased with serum ChE levels (p < 0.001).

2.Higher ChE levels were associated with higher body mass index (BMI) (p < 0.001), dyslipidaemia (p < 0.001), including elevated low-density lipoprotein cholesterol (LDL-C) (p < 0.001), triglycerides (TG) (p < 0.001), and serum albumin (p < 0.001), as well as younger age (p < 0.001).

3.At a ChE level of 286 IU/L, the specificity and sensitivity for myocardial ischemia were 0.599 and 0.658, respectively.

 4.Elevated serum ChE levels (OR = 1.66, p < 0.001) were an independent risk factor for myocardial ischemia in patients with suspected stable CAD.

These findings suggest that serum ChE levels may be a valuable diagnostic biomarker for myocardial ischemia in patients with suspected stable CAD [22,23].

## Other Inflammatory and immunological biomarkers

In a prospective cohort study known as the Study of Ageing and Longevity in the Sirente Geographical Area, researchers investigated whether interleukin-6 (IL-6), C-reactive protein (CRP), and tumor necrosis factor-alpha (TNF-α) protein levels could predict all-cause mortality in community-dwelling older adults [24]. The study included 362 participants aged 80 years or older living in a mountain community in Italy. Participants were categorized based on the mean of three inflammatory markers: IL-6 (2.08 pg/mL), TNF-α (1.43 pg/mL), and CRP (3.08 mg/L). Additionally, a summary inflammation score was calculated. The primary outcome was the risk of death after four years of follow-up. During the four-year follow-up period, 150 deaths occurred.

Unadjusted analyses revealed that elevated levels of each of the three markers were associated with increased mortality. After adjusting for potential risk factors, high levels of IL-6 (hazard ratio (HR) = 2.18, 95% confidence interval (CI) = 1.29–3.69) and CRP (HR = 2.58, 95% CI = 1.52–4.40) remained significantly associated with a higher risk of death. However, the association between TNF-α protein levels and mortality was no longer significant (HR = 1.26, 95% CI = 0.74–2.15). Thus, a composite summary score of inflammation demonstrated a strong association with mortality, with the highest risk estimated for those with all three inflammatory markers above the median This study suggests that lower levels of inflammatory markers are linked to improved survival in older adults, independent of age and other clinical and functional variables [24].

Older adults exhibit a higher level of lymphoproliferation, characterized by increased CD10+, CD25+ T-lymphocytes, and CD16+ natural killer (NK) cells compared to middle-aged individuals. In the peripheral blood of elderly individuals, up to 95% of NK cells express high levels of CD16 but low levels of CD56. These NK cells exhibit high cytolytic activity but impaired secretion of TNF-α, IFN-γ, IL-5, IL-8, and colony-stimulating factors. Consequently, the reduced NK cell concentration in the peripheral blood of elderly individuals may diminish their ability to combat intracellular infections effectively.

Recent studies have highlighted the role of immune inflammation in atherosclerosis development. Cytokines, critical mediators of immune inflammation, can be produced by altered endothelial cells and modulate vascular wall functions. TNF-α activates leukocytes involved in inflammatory reactions and induces the expression of adhesion molecules on endothelial cells, facilitating the adhesion of neutrophils, monocytes, and lymphocytes, leading to inflammatory infiltration of the vascular wall. IL-6, acting downstream of TNF-α, contributes to endothelial dysfunction and may trigger acute coronary events. Elevated IL-6 levels in arterial walls correlate with markers of endothelial dysfunction and signs of insulin resistance, which are associated with an increased risk of vascular damage and atherosclerosis progression.

C-reactive protein (CRP) is another marker of cardiovascular risk. Inflammation, as reflected by increased CRP levels, contributes to the development of vascular atherosclerosis. Additionally, under experimental conditions, CRP has been shown to upregulate the expression of type II AG receptors on vascular smooth muscle cells [8,17,22,25-27].

A study by Niki Murtzi and colleagues discovered that a genetic predisposition to downregulating IL-6 signaling, weighted by CRP levels, was associated with a lower risk of frailty [28]. IL-6, a pro-inflammatory cytokine implicated in various age-related ailments, including frailty, plays a significant role in this finding. Frailty is a syndrome characterized by physical weakness, fatigue, slowness, and unintentional weight loss, increasing the risk of hospitalization, institutionalization, and death. This finding supports a potential causal link between IL-6 signaling and frailty, suggesting that reducing IL-6 levels may lower frailty risk [28].

A study by Niki Murtzi and colleagues found that IL-6, a pro-inflammatory cytokine that plays a role in a variety of age-related diseases, including frailty, a genetic predisposition to downregulation of IL-6 signaling, weighted by CRP levels, was associated with a lower risk of frailty [28]. Frailty is a syndrome characterized by physical weakness, fatigue, slowness, and unintentional weight loss. It is a major risk factor for hospitalization, institutionalization, and death. This finding supports a potential causal effect of IL-6 signaling on frailty and suggests that reducing IL-6 levels may reduce the risk of frailty.

# Conclusion

A review of the available literature suggests that survival to the current highest age in low-mortality countries is supported by protection from cardiovascular disease, given the inherent susceptibility of this system to oxidative stress and inflammation and its central role in maintaining oxygen and metabolite delivery to major organ systems. These findings underscore the need to identify specific cardiac markers that can effectively predict premature ageing and prevent adverse outcomes during ageing.

Median NT-proBNP levels increased consistently with age, regardless of cardiovascular status. Serum ChE levels may be a valuable diagnostic biomarker in patients with suspected stable CAD.

In the context of inflammatory markers, centenarians exhibited fewer signs of inflammation. Inflammatory peptides were either absent or present in lower abundance than in younger cohorts, while levels of anti-inflammatory cytokines such as IL-10 and transforming growth factor β were elevated in centenarians.

Currently, the primary objectives in the review of ageing predictors are as follows:

1.To determine the characteristics of healthy and pathological (early) ageing, identifying risk factors (clinical, immunological, lifestyle-related, and functional state of the cardiovascular system, among others).

 2.To assess the state of T-cell immunity in different types of ageing (healthy and previously pathological) and to investigate the population profile of lymphocytes, expression of activation markers, and functional state of immune cells (based on the expression of cytokines, primarily IL-6 and TNF, as the most significant markers of ageing) in different subtypes of ageing.

**Bibliography:**

1. World Health Organization. Website. [Cited 1 October 2022]. Available from URL:

<https://www.who.int/ru/news-room/fact-sheets/detail/ageing-and-health>.

1. Zhang ZD, Milman S, Lin JR, Wierbowski S, Yu H, Barzilai N, Gorbunova V, Ladiges WC, Niedernhofer LJ, Suh Y, Robbins PD, Vijg J. Genetics of extreme human longevity to guide drug discovery for healthy ageing. Nat Metab. 2020 Aug;2(8):663-672. doi: 10.1038/s42255-020-0247-0.

3.Москалев А.А., Прошкина Е.Н., Белый А.А., Соловьев И.А. Генетика старения и долголетия. Вавиловский журнал генетики и селекции. 2016;20(4):426-440. DOI 10.18699/VJ16.171

 Moskalev A.A., Proshkina E.N., Belyi A.A., Solovyev I.A. Genetics of aging and longevity. Vavilovskii Zhurnal Genetiki i Selektsii =Vavilov Journal of Genetics and Breeding. 2016;20(4):426-440. DOI 10.18699/VJ16.171A.S.

4. Андрей С. Б., Игорь С.Б. Постгеномная теория старения человека и научное обоснование применения маломанипулированных биомедицинских клеточных препаратов аутологичного костного мозга для антистарения, увеличения продолжительности жизни и долголетия человека. Научный обозреватель -2020-Т-8-С-116.

Andrey S.B., Igor S.B. Postgenomic theory of human aging and scientific rationale for the use of low-manipulation biomedical cell preparations of autologous bone marrow for anti-aging, increasing human life expectancy and longevity. Scientific observer -2020-T-8-S-116.

5.Savji N, Rockman CB, Skolnick AH, Guo Y, Adelman MA, Riles T, Berger JS. Association between advanced age and vascular disease in different arterial territories: a population database of over 3.6 million subjects. J Am Coll Cardiol. 2013 Apr 23;61(16):1736-43. doi: 10.1016/j.jacc.2013.01.054.

6. Justice JN, Ferrucci L, Newman AB, Aroda VR, Bahnson JL, Divers J, Espeland MA, Marcovina S, Pollak MN, Kritchevsky SB, Barzilai N, Kuchel GA. A framework for selection of blood-based biomarkers for geroscience-guided clinical trials: report from the TAME Biomarkers Workgroup. Geroscience. 2018 Dec;40(5-6):419-436. doi: 10.1007/s11357-018-0042-y.

7. Moreno-Villanueva M, Bürkle A. Epigenetic and redox biomarkers: Novel insights from the MARK-AGE study. Mech Ageing Dev. 2019 Jan; 177:128-134. doi: 10.1016/j.mad.2018.06.006.

8.Hirata, T., Arai, Y., Yuasa, S., Abe, Y., Takayama, M., Sasaki, T., … Hirose, N. (2020). Associations of cardiovascular biomarkers and plasma albumin with exceptional survival to the highest ages. Nature Communications, 11(1). doi:10.1038/s41467-020-17636-0

 9.lexander Bürkle, María Moreno-Villanueva, Jürgen Bernhard, María Blasco, Gerben Zondag, Jan H.J. Hoeijmakers, Olivier Toussaint, Beatrix Grubeck-Loebenstein, Eugenio Mocchegiani, Sebastiano Collino, Efstathios S. Gonos, Ewa Sikora, Daniela Gradinaru, Martijn Dollé, Michel Salmon, Peter Kristensen, Helen R. Griffiths, Claude Libert, Tilman Grune, Nicolle Breusing, Andreas Simm, Claudio Franceschi, Miriam Capri, Duncan Talbot, Paola Caiafa, Bertrand Friguet, P. Eline Slagboom, Antti Hervonen, Mikko Hurme, Richard Aspinall.MARK-AGE biomarkers of ageing,Mechanisms of Ageing and Development,2015;151: 2-12.doi.org/10.1016/j.mad.2015.03.006.

 10. Sebastiani P, Thyagarajan B, Sun F, Honig LS, Schupf N, Cosentino S, Feitosa MF, Wojczynski M, Newman AB, Montano M, Perls TT. Age and Sex Distributions of Age-Related Biomarker Values in Healthy Older Adults from the Long Life Family Study. J Am Geriatr Soc. 2016 Nov;64(11):e189-e194. doi: 10.1111/jgs.1452

11. Takayama M, Hirose N, Arai Y, Gondo Y, Shimizu K, Ebihara Y, Yamamura K, Nakazawa S, Inagaki H, Masui Y, Kitagawa K. Morbidity of Tokyo-area centenarians and its relationship to functional status. J Gerontol A Biol Sci Med Sci. 2007 Jul;62(7):774-82. doi: 10.1093/gerona/62.7.774.

12.Щукин Ю.В., Березин И.И., Медведева Е.А., Селезнев Е.И., Дьячков В.А., Слатова Л.Н. о значении галектина-3 как маркера и медиатора эндогенного воспаления и окислительно-нитрозилирующего стресса у больных хронической сердечной недостаточностью. Российский кардиологический журнал. 2013;(2):45-49. [doi.org/10.15829/1560-4071-2013-2-45-49](https://doi.org/10.15829/1560-4071-2013-2-45-49)

 Shchukin Yu.B., Berezin I.I., Medvedeva E.A., Seleznev E.I., Dyachkov V.A., Slatova L.N. Galectin-3 as a marker and mediator of endogenous inflammation and nitrosylation oxidative stress in patients with chronic heart failure. *Russian Journal of Cardiology*. 2013;(2):45-49. (In Russ.) [doi.org/10.15829/1560-4071-2013-2-45-49](https://doi.org/10.15829/1560-4071-2013-2-45-49)

 13. Yoshida Y, Nakanishi K, Daimon M, Ishiwata J, Sawada N, Hirokawa M, Kaneko H, Nakao T, Mizuno Y, Morita H, Di Tullio MR, Homma S, Komuro I. Alteration of Cardiac Performance and Serum B-Type Natriuretic Peptide Level in Healthy Aging. J Am Coll Cardiol. 2019 Oct 8;74(14):1789-1800. doi: 10.1016/j.jacc.2019.07.080.

 **14. Tseylikman V.E., Lukin A.A.** **International Scientific Research Journal,.**Т**he effect of oxidative stress on the human body 2022;**[3,206-2011(117): doi.org/10.23670/IRJ.2022.117.3.037](https://research-journal.org/en/archive/3-117-2022-march) .

 Цейликман В.Е., Лукин А.А. Международный научно-исследовательский журнал. Влияние окислительного стресса на организм человека 2022;3,206-2011(117): doi.org/10.23670/IRJ.2022.117.3.037.

 15. Щукин Ю.В., Березин И.И., Медведева Е.А., Селезнев Е.И., Дьячков В.А., Слатова Л.Н. о значении галектина-3 как маркера и медиатора эндогенного воспаления и окислительно-нитрозилирующего стресса у больных хронической сердечной недостаточностью. Российский кардиологический журнал. 2013;(2):45-49. doi.org/10.15829/1560-4071-2013-2-45-49

 Shchukin Yu.B., Berezin I.I., Medvedeva E.A., Seleznev E.I., Dyachkov V.A., Slatova L.N. Galectin-3 as a marker and mediator of endogenous inflammation and nitrosylation oxidative stress in patients with chronic heart failure. Russian Journal of Cardiology. 2013;(2):45-49. doi.org/10.15829/1560-4071-2013-2-45-49

 16. Камышникова Л.А., Ефремова О.А. Влияние коморбидности на ремоделирование и дисфункцию миокарда при сердечной недостаточности с сохранной фракцией выброса. Клиническая Медицина. 2017 год; 95(12): 1070–1076 oai: dspace.bsu.edu.ru:123456789/24160.

 Kamyshnikova LA, Efremova OA Impact of comorbidities on myocardial remodeling and dysfunction in heart failure with preserved ejection fraction. Klinicheskaya Meditsina. 2017; 95(12): 1070–1076 [oai: dspace.bsu.edu.ru:123456789/24160](https://api.core.ac.uk/oai/oai%3Adspace.bsu.edu.ru%3A123456789/24160)

 17.Полунина Е.А. Сывороточный уровень продуктов глубокого окисления белков и активность супероксиддисмутазы как маркеров оксидативного стресса у пациентов с хронической сердечной недостаточностью. Кубанский научный медицинский вестник. 2019; 26(1): 122–130. <https://doi.org/10.25207/1608-6228-2019-26-1-122-130>

 Polunina E.A. Serum level of products of deep oxidation of proteins and activity of superoxide dismutase as markers of oxidative stress in patients with chronic heart failure. Kuban scientific medical journal. 2019; 26(1): 122–130. <https://doi.org/10.25207/1608-6228-2019-26-1-122-130>

 18.Chen DC, Potok OA, Rifkin D, Estrella MM. Advantages, Limitations, and Clinical Considerations in Using Cystatin C to Estimate GFR. Kidney360. 2022 Aug 23;3(10):1807-1814. doi: 10.34067/KID.0003202022.

 19. Moreno-Villanueva M, Bürkle A. Epigenetic and redox biomarkers: Novel insights from the MARK-AGE study. Mech Ageing Dev. 2019 Jan; 177:128-134.

doi: 10.1016/j.mad.2018.06.006.

 20.Ageing affects subtelomeric DNA methylation in blood cells from a large European population enrolled in the MARK-AGE study Bacalini, M.G., Reale, A., Malavolta, M., Ciccarone, F., Moreno-Villanueva, M., Dollé, M.E.T. Jansen, E., Grune, T., Gonos, E.S., Schön, C., Bernhardt, J., Grubeck-Loebenstein, B., Sikora, E., Toussaint, O., Debacq-Chainiaux, F., Capri, M., Hervonen, A., Hurme, M., Slagboom, P.E., ... Zampieri, M. (2021). Ageing affects subtelomeric DNA methylation in blood cells from a large European population enrolled in the MARK-AGE study. GeroScience, 43(3), 1283-1302. 2021.<https://doi.org/10.1007/s11357-021-00347-9>

 21. Mito T, Takemoto M, Antoku Y, Tanaka A, Matsuo A, Hida S, Yoshitake K, Kosuga KI, Miura SI. Influence of Serum Cholinesterase Levels on Patients Suspected of Having Stable Coronary Artery Disease. Intern Med. 2021 Apr 15;60(8):1145-1150. doi: 10.2169/internalmedicine.5719-20.

22.Zou J, Chen Z, Liang C, Fu Y, Wei X, Lu J, Pan M, Guo Y, Liao X, Xie H, Wu D, Li M, Liang L, Wang P, Wang Q. Trefoil Factor 3, Cholinesterase and Homocysteine: Potential Predictors for Parkinson's Disease Dementia and Vascular Parkinsonism Dementia in Advanced Stage. Aging Dis. 2018 Feb 1;9(1):51-65. doi: 10.14336/AD.2017.0416.

23. Giovannini, S., Onder, G., Liperoti, R., Russo, A., Carter, C., Capoluongo, E., Pahor, M., Bernabei, R. and Landi, F. (2011), Interleukin-6, C-Reactive Protein, and Tumor Necrosis Factor-Alpha as Predictors of Mortality in Frail, Community-Living Elderly Individuals. Journal of the American Geriatrics Society, 59: 1679-1685. <https://doi.org/10.1111/j.1532-5415.2011.03570>.

24. Vasto S, Scapagnini G, Bulati M, Candore G, Castiglia L, Colonna-Romano G, Lio D, Nuzzo D, Pellicano M, Rizzo C, Ferrara N, Caruso C. Biomarkes of aging. Front Biosci (Schol Ed). 2010 Jan 1;2(2):392-402. doi: 10.2741/s72.

25. Engelfriet PM, Jansen EH, Picavet HS, Dollé ME. Biochemical markers of aging for longitudinal studies in humans. Epidemiol Rev. 2013;35(1):132-51. doi: 10.1093/epirev/mxs011.

24. Iryna Rusanova, María E. Diaz-Casado, Marisol Fernández-Ortiz, Paula Aranda-Martínez, Ana Guerra-Librero, Francisco J. García-García, Germaine Escames, Leocadio Mañas, Darío Acuña-Castroviejo, "Analysis of Plasma MicroRNAs as Predictors and Biomarkers of Aging and Frailty in Humans", *Oxidative Medicine and Cellular Longevity*, vol. 2018, Article 9 pages, 2018. https://doi.org/10.1155/2018/7671850

25.Chow SL, Maisel AS, Anand I, Bozkurt B, de Boer RA, Felker GM, Fonarow GC, Greenberg B, Januzzi JL Jr, Kiernan MS, Liu PP, Wang TJ, Yancy CW, Zile MR; American Heart Association Clinical Pharmacology Committee of the Council on Clinical Cardiology; Council on Basic Cardiovascular Sciences; Council on Cardiovascular Disease in the Young; Council on Cardiovascular and Stroke Nursing; Council on Cardiopulmonary, Critical Care, Perioperative and Resuscitation; Council on Epidemiology and Prevention; Council on Functional Genomics and Translational Biology; and Council on Quality of Care and Outcomes Research. Role of Biomarkers for the Prevention, Assessment, and Management of Heart Failure: A Scientific Statement From the American Heart Association. Circulation. 2017 May 30;135(22):e1054-e1091. doi: 10.1161/CIR.0000000000000490.

26.Mourtzi, N, Charisis, S, Tsapanou, A, et al. Genetic propensity for cerebral amyloidosis and risk of mild cognitive impairment and Alzheimer's disease within a cognitive reserve framework. Alzheimer's Dement. 2023; 19: 3794–3805. https://doi.org/10.1002/alz.12980